Cargando…

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the last few years, patients with heart failure w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falco, Luigi, Brescia, Benedetta, Catapano, Dario, Martucci, Maria Luigia, Valente, Fabio, Gravino, Rita, Contaldi, Carla, Pacileo, Giuseppe, Masarone, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531735/ https://www.ncbi.nlm.nih.gov/pubmed/37754817 http://dx.doi.org/10.3390/jcdd10090388

Ejemplares similares

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

How to Select Patients for Left Ventricular Assist Devices? A Guide for Clinical Practice
por: Masarone, Daniele, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

Levosimendan as a “Bridge to Optimization” in Patients with Advanced Heart Failure with Reduced Ejection—A Single-Center Study
por: Masarone, Daniele, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2020)

Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study
por: Masarone, Daniele, et al.
Publicado: (2019)

The ABC of Heart Transplantation—Part 1: Indication, Eligibility, Donor Selection, and Surgical Technique
por: Masarone, Daniele, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy
por: Contaldi, Carla, et al.
Publicado: (2023)

The Effects of Device-Based Cardiac Contractility Modulation Therapy on Left Ventricle Global Longitudinal Strain and Myocardial Mechano-Energetic Efficiency in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2022)

Pathophysiology-Based Management of Acute Heart Failure
por: Falco, Luigi, et al.
Publicado: (2023)

The Role of Echocardiography in the Management of Heart Transplant Recipients
por: Masarone, Daniele, et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update
por: Masarone, Daniele, et al.
Publicado: (2018)

Effects of Cardiac Contractility Modulation Electrodes on Tricuspid Regurgitation in Patients with Heart Failure with Reduced Ejection Fraction: A Pilot Study
por: Masarone, Daniele, et al.
Publicado: (2022)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Management of Arrhythmias in Heart Failure
por: Masarone, Daniele, et al.
Publicado: (2017)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Left Ventricular Assist Device Implantation in a Thrombosed Apical Aneurysm
por: Masarone, Daniele, et al.
Publicado: (2021)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Berlin Heart EXCOR® pediatric ventricular assist device in a patient with Sotos syndrome: a case report
por: Gravino, Rita, et al.
Publicado: (2019)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease
por: Limongelli, Giuseppe, et al.
Publicado: (2018)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Left Atrial Volume during Stress Is Associated with Increased Risk of Arrhythmias in Patients with Hypertrophic Cardiomyopathy
por: Limongelli, Giuseppe, et al.
Publicado: (2019)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
por: Sahana, Urjosee, et al.
Publicado: (2023)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p3ebnfgjvt02lsn40pttduj0kl